The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1.
 
Claire Friedman
Honoraria - GlaxoSmithKline; MJH Healthcare Holdings, LLC
Consulting or Advisory Role - AADi; Arch Oncology; Bristol Myers Squibb; Loxo/Lilly
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech (Inst); Hotspot Therapeutics (Inst); Immunocore (Inst); Loxo/Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Seagen (Inst); Volastra Therapeutics (Inst)
Travel, Accommodations, Expenses - Puma Biotechnology
(OPTIONAL) Uncompensated Relationships - Genentech; Marengo Therapeutics; Merck
 
Ryan Sullivan
Consulting or Advisory Role - BridGene Biosciences; Bristol-Myers Squibb; Marengo Therapeutics; Merck; Novartis; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Georgimmune (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)
 
Nicholas Tschernia
No Relationships to Disclose
 
Guru Sonpavde
Employment - Exact Sciences (I); Myriad Genetics (I)
Honoraria - Grand Rounds in Urology; Ideology Health; Onviv; PeerView; PrecisCa; UpToDate
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; Bicycle Therapeutics; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Janssen; Kura Oncology; Loxo/Lilly; Loxo/Lilly; Lucence; Merck; Pfizer; Scholar Rock; Seagen; Syapse; Vial
Speakers' Bureau - Astellas Pharma; AVEO; Bayer; Exelixis; Gilead Sciences; INFORMAÇÃO BRASILEIRA DE ONCOLOGIA; Janssen Oncology; Medscape; Merck; Natera; Pfizer; Research to Practice; Seagen
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Sumitomo Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb
Other Relationship - Bristol-Myers Squibb; Elsevier; G1 Therapeutics; Merck; Mereo BioPharma; QED Therapeutics
 
Mercedes Herrera
Speakers' Bureau - AstraZeneca Spain
Travel, Accommodations, Expenses - Roche
 
Kai He
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Obsidian Therapeutics; oncoc4; Perthera; Pfizer
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)
 
Marijo Bilusic
Research Funding - Bicycle Therapeutics (Inst); Hookipa Biotech (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Proviva Therapeutics (Inst); Surface Oncology (Inst)
 
Elena Garralda
Employment - Next Oncology
Stock and Other Ownership Interests - 1TRIALSP
Consulting or Advisory Role - Abbvie; Alentis Therapeutics; Amgen; Anaveon; Astex Pharmaceuticals; Boehringer Ingelheim; Daiichi Sankyo/Lilly; Ellipses Pharma; Genmab; Gilead Sciences; Greywolf; Hengrui Therapeutics; Incyte; Janssen; Marengo Therapeutics; Medpace; Medscape; Pfizer; Roche; Sanofi; Seagen; Skypta; Sotio
Speakers' Bureau - AEFI; Alcura; Aran; AstraZeneca; CDDF; Doctaforum; ESMO; Fundación ECO; Fundación SEOM; Horizon CME; Karger Publishers; Medscape; MeetingPharma; MSD; Novartis; PPD Global; Roche; Seagen; Springer Nature; Tactics; The Ricky Rubio Fundation
Research Funding - Anaveon; AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst)
 
Alberto Hernando-Calvo
Honoraria - Slingshot insights
Consulting or Advisory Role - Karger Publishers
Research Funding - Gilead Sciences (Inst)
 
Ann Silk
Stock and Other Ownership Interests - gral; Illumina
Consulting or Advisory Role - Merck; Regeneron
Research Funding - Checkmate Pharmaceuticals (Inst); Merck (Inst); Morphogenesis (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Matthieu Roulleaux-Dugage
No Relationships to Disclose
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Manuel Pedregal
No Relationships to Disclose
 
Muhammad Saif
Consulting or Advisory Role - US WorldMeds
Research Funding - Amal Therapeutics; BeiGene; Genentech; GlaxoSmithKline; IDEAYA Biosciences; OBI Pharma; SpringWorks Therapeutics; Yiviva
Patents, Royalties, Other Intellectual Property - UpToDate
 
Kevin Chin
No Relationships to Disclose
 
Zhen Su
No Relationships to Disclose
 
Ke Liu
Employment - Marengo Therapeutics
Leadership - Marengo Therapeutics
 
Lillian Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca; Daiichi Sankyo/UCB Japan; Gilead Sciences; GlaxoSmithKline; Incyte; LTZ Therapeutics; Marengo Therapeutics; Medicenna; Merck; Navire; Nerviano Medical Sciences; Pangea; Pangea; Relay Therapeutics; Roche; Seagen; Tubulis GmbH; Voronoi Health Analytics
Research Funding - 23andMe (Inst); Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); LegoChem Biosciences (Inst); Loxo/Lilly (Inst); Marengo Therapeutics (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Takara Bio (Inst)
 
James Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Marengo Therapeutics (Inst); Merck (Inst); NextCure (Inst); PDS Biotechnology (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
Aurelien Marabelle
Stock and Other Ownership Interests - Adagene; Centessa Pharmaceuticals; Deka Biosciences; HiFiBiO Therapeutics; HotSpot Therapeutics; Lytix Biopharma; Marengo Therapeutics; Shattuck Labs
Honoraria - ESMO; European Journal of Cancer; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Adagene; Andera; Asgard Therapeutics; Centessa Pharmaceuticals; Daiichi Sankyo Europe GmbH; Deka Biosciences; Grey Wolf Therapeutics; Guidepoint Global; HiFiBiO Therapeutics; Hotspot Therapeutics; ImCheck therapeutics; Innate Pharma; Johnson & Johnson/Janssen; Lytix Biopharma; Medicxi; MSD; Pathios Therapeutics; Pegaone; Pierre Fabre
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - HiFiBiO Therapeutics; Marengo Therapeutics; Pathios Therapeutics
Other Relationship - Elsevier